252 related articles for article (PubMed ID: 29264740)
1. CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens.
Qin XY; Lu J; Li GX; Wen L; Liu Y; Xu LP; Chang YJ; Liu KY; Jiang ZF; Huang XJ
Ann Hematol; 2018 Mar; 97(3):485-495. PubMed ID: 29264740
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms of nuclear factor-κB family genes are associated with development of multiple myeloma and treatment outcome in patients receiving bortezomib-based regimens.
Du J; Huo J; Shi J; Yuan Z; Zhang C; Fu W; Jiang H; Yi Q; Hou J
Haematologica; 2011 May; 96(5):729-37. PubMed ID: 21228035
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donor.
Qin XY; Wang Y; Li GX; Qin YZ; Wang FR; Xu LP; Chen H; Han W; Wang JZ; Zhang XH; Chang YJ; Liu KY; Jiang ZF; Huang XJ
J Transl Med; 2016 Apr; 14():100. PubMed ID: 27118383
[TBL] [Abstract][Full Text] [Related]
5. PDCD1 and PDCD1LG1 polymorphisms affect the susceptibility to multiple myeloma.
Kasamatsu T; Awata M; Ishihara R; Murakami Y; Gotoh N; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Saitoh T; Murakami H
Clin Exp Med; 2020 Feb; 20(1):51-62. PubMed ID: 31620907
[TBL] [Abstract][Full Text] [Related]
6. CTLA4 gene polymorphisms influence the incidence of infection after renal transplantation in Chinese recipients.
Guo Y; Guo F; Wei C; Qiu J; Liu Y; Fang Y; Gao J
PLoS One; 2013; 8(8):e70824. PubMed ID: 24015180
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms and Circulating Plasma Protein Levels of Immune Checkpoints (CTLA-4 and PD-1) Are Associated With Posner-Schlossman Syndrome in Southern Chinese.
Huang X; Liu X; Ye Y; Zhang T; Mei S; Zhu T; Peng S; Cai J; Yan Z; Zeng K; Nie D; Sun L; Hou X; Zhao J
Front Immunol; 2021; 12():607966. PubMed ID: 33717091
[TBL] [Abstract][Full Text] [Related]
8. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T-lymphocyte antigen 4 gene polymorphism influences the incidence of symptomatic human cytomegalovirus infection after renal transplantation.
Misra MK; Pandey SK; Kapoor R; Sharma RK; Agrawal S
Pharmacogenet Genomics; 2015 Jan; 25(1):19-29. PubMed ID: 25356901
[TBL] [Abstract][Full Text] [Related]
10. Association of CTLA-4 polymorphisms with increased risks of myasthenia gravis.
Li F; Yuan W; Wu X
Ann Hum Genet; 2018 Nov; 82(6):358-369. PubMed ID: 30009380
[TBL] [Abstract][Full Text] [Related]
11. Association of CTLA-4 gene polymorphism with end-stage renal disease and renal allograft outcome.
Misra MK; Kapoor R; Pandey SK; Sharma RK; Agrawal S
J Interferon Cytokine Res; 2014 Mar; 34(3):148-61. PubMed ID: 24313821
[TBL] [Abstract][Full Text] [Related]
12. CTLA-4 and CD28 genes' polymorphisms and renal cell carcinoma susceptibility in the Polish population--a prospective study.
Tupikowski K; Partyka A; Kolodziej A; Dembowski J; Debinski P; Halon A; Zdrojowy R; Frydecka I; Karabon L
Tissue Antigens; 2015 Nov; 86(5):353-61. PubMed ID: 26403483
[TBL] [Abstract][Full Text] [Related]
13. Evidence of Association between CTLA-4 Gene Polymorphisms and Colorectal Cancers in Saudi Patients.
Al-Harbi N; Abdulla MH; Vaali-Mohammed MA; Bin Traiki T; Alswayyed M; Al-Obeed O; Abid I; Al-Omar S; Mansour L
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107632
[TBL] [Abstract][Full Text] [Related]
14. PTPN22 and CTLA-4 Polymorphisms Are Associated With Polyglandular Autoimmunity.
Houcken J; Degenhart C; Bender K; König J; Frommer L; Kahaly GJ
J Clin Endocrinol Metab; 2018 May; 103(5):1977-1984. PubMed ID: 29409002
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 polymorphisms and predisposition to digestive system malignancies: a meta-analysis of 31 published studies.
Li J; Wang W; Sun Y; Zhu Y
World J Surg Oncol; 2020 Mar; 18(1):55. PubMed ID: 32178688
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte antigen 4 (CTLA4) +49AG and CT60 gene polymorphisms in Alopecia Areata: a case-control association study in the Italian population.
Megiorni F; Mora B; Maxia C; Gerardi M; Pizzuti A; Rossi A
Arch Dermatol Res; 2013 Sep; 305(7):665-70. PubMed ID: 23567921
[TBL] [Abstract][Full Text] [Related]
17. Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies.
Fang M; Huang W; Mo D; Zhao W; Huang R
Cell Physiol Biochem; 2018; 47(1):414-427. PubMed ID: 29794444
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma.
Liu Y; He Z; Feng D; Shi G; Gao R; Wu X; Song W; Yuan W
DNA Cell Biol; 2011 Dec; 30(12):1051-5. PubMed ID: 21612409
[TBL] [Abstract][Full Text] [Related]
19. Effect of CTLA-4 gene polymorphisms on long-term kidney allograft function in Han Chinese recipients.
Guo Y; Gao J; Gao S; Shang M; Guo F
Oncotarget; 2016 Apr; 7(17):23088-95. PubMed ID: 27081086
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
